@article{d5de807dd1924cab9a55cb820b3c5391,
title = "Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial: The Lancet Oncology",
abstract = "Background: Tumour Treating Fields (TTFields) are a regional, antimitotic treatment for solid tumours, which is based on the delivery of low-intensity alternating electric fields. The aim of the STELLAR study was to test the activity of TTFields delivered to the thorax in combination with systemic chemotherapy for the front-line treatment of patients with unresectable malignant pleural mesothelioma. Methods: STELLAR was a prospective, single-arm, phase 2 trial done at 12 European academic and non-academic sites (five in Italy, three in Poland, one in France, one in Belgium, one in Spain, and one in the Netherlands) for treatment-naive patients with histologically confirmed unresectable malignant pleural mesothelioma. Patients were aged at least 18 years, had an Eastern Cooperative Oncology Group performance status of 0–1, and at least one measurable or evaluable lesion according to modified Response Evaluation Criteria in Solid Tumors for mesothelioma. Patients received continuous TTFields at a frequency of 150 kHz to the thorax and concomitant chemotherapy with intravenous pemetrexed (500 mg/m2 on day 1) plus intravenous platinum (either cisplatin 75 mg/m2 on day 1 or carboplatin area under the curve 5 on day 1) every 21 days for up to six cycles. Patients not progressing after completion of chemotherapy received TTFields as maintenance treatment until progression, patient or physician decision, or unacceptable toxic effects. The primary endpoint of the trial was overall survival. Survival analyses were done in the intention-to-treat population, and safety analyses were done in all patients who received at least 1 day of TTFields treatment. This trial is registered with ClinicalTrials.gov, NCT02397928. Findings: Between Feb 9, 2015 and March 21, 2017, 80 patients were enrolled in the study. Median follow-up was 12·5 months (IQR 7·4–16·6). Median overall survival was 18·2 months (95% CI 12·1–25·8). The most common grade 3 or worse adverse events were anaemia (nine [11%] patients), neutropenia (seven [9%]), and thrombocytopenia (four [5%]). Skin reaction was the only adverse event associated with TTFields and was reported as grade 1–2 in 53 (66%) patients, and as grade 3 in four (5%) patients. No treatment-related deaths were observed. Interpretation: The trial showed encouraging overall survival results, with no increase in systemic toxicity. TTFields (150 kHz) delivered to the thorax concomitant with pemetrexed and platinum was an active and safe combination for front-line treatment of unresectable malignant pleural mesothelioma. Further investigation in a randomised trial is warranted. Funding: Novocure. {\textcopyright} 2019 Elsevier Ltd",
keywords = "carboplatin, cisplatin, doxorubicin, gemcitabine, pemetrexed, vinorelbine tartrate, adult, aged, anemia, Article, asthenia, atrial fibrillation, Belgium, bronchopneumonia, cancer growth, cancer therapy, candidemia, cholelithiasis, clinical decision making, constipation, controlled study, coughing, drug dose reduction, drug effect, drug safety, drug withdrawal, dyspnea, epilepsy, fatigue, febrile neutropenia, female, follow up, France, gastric ulcer bleeding, heart tamponade, histopathology, human, leukopenia, liver toxicity, lung embolism, major clinical study, male, multicenter study, multiple cycle treatment, nausea, neck pain, nephrotoxicity, Netherlands, neutropenia, oliguria, overall survival, pericardial effusion, phase 2 clinical trial, pleura mesothelioma, pneumonia, Poland, population research, priority journal, prospective study, pruritus, randomized controlled trial, respiratory failure, skin manifestation, Spain, stomach ulcer, thorax electric field, thorax pain, thrombocytopenia, thrush, tumor treating field, vascular disease, vomiting",
author = "G.L. Ceresoli and J.G. Aerts and R. Dziadziuszko and R. Ramlau and S. Cedres and {van Meerbeeck}, J.P. and M. Mencoboni and D. Planchard and A. Chella and L. Crin{\`o} and M. Krzakowski and J. R{\"u}ssel and A. Maconi and L. Gianoncelli and F. Grosso",
note = "Cited By :5 Export Date: 26 February 2020 CODEN: LOANB Correspondence Address: Ceresoli, G.L.; Department of Oncology, Cliniche Humanitas GavazzeniItaly; email: giovanni_luca.ceresoli@gavazzeni.it Chemicals/CAS: carboplatin, 41575-94-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; doxorubicin, 23214-92-8, 25316-40-9; gemcitabine, 103882-84-4; pemetrexed, 137281-23-3, 150399-23-8; vinorelbine tartrate, 125317-39-7, 71486-22-1 Manufacturers: Novocure, Israel Funding text 1: The study protocol and site enrolment data will be available to anyone who wishes to access them in the appendix of this Article, immediately following publication and with no end date. Individual patient data underlying the results reported in this Article will not be available. Acknowledgments The study was funded and sponsored by Novocure. LG was supported by Fondazione Buzzi Unicem (Casale Monferrato, Italy). The authors would like to thank the participating patients and their families and caregivers, and all the investigators and site personnel. References: Robinson, B.W., Musk, A.W., Lake, R.A., Malignant mesothelioma (2005) Lancet, 366, pp. 397-408; Delgermaa, V., Takahashi, K., Park, E.K., Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008 (2011) Bull World Health Organ, 89, pp. 716-724; van Meerbeeck, J.P., Gaafar, R., Manegold, C., Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada (2005) J Clin Oncol, 23, pp. 6881-6889; Vogelzang, N.J., Rusthoven, J.J., Symanowski, J., Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma (2003) J Clin Oncol, 21, pp. 2636-2644; Ceresoli, G.L., Zucali, P.A., Favaretto, A.G., Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma (2006) J Clin Oncol, 24, pp. 1443-1448; Kindler, H.L., Ismaila, N., Armato, S.G., III, Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline (2018) J Clin Oncol, 36, pp. 1343-1373; Zalcman, G., Mazieres, J., Margery, J., Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial (2016) Lancet, 387, pp. 1405-1414; Kirson, E.D., Dbaly, V., Tovarys, F., Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) Proc Natl Acad Sci USA, 104, pp. 10152-10157; Kirson, E.D., Gurvich, Z., Schneiderman, R.S., Disruption of cancer cell replication by alternating electric fields (2004) Cancer Res, 64, pp. 3288-3295; Giladi, M., Schneiderman, R.S., Voloshin, T., Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells (2015) Sci Rep, 5; Mun, E.J., Babiker, H.M., Weinberg, U., Tumor-treating fields: a fourth modality in cancer treatment (2018) Clin Cancer Res, 24, pp. 266-275; Chang, E., Patel, C.B., Pohling, C., Tumor treating fields increase membrane permeability in glioblastoma cells (2018) Cell Death Discov, 4, p. 113; Lacouture, M.E., Davis, M.E., Elzinga, G., Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma (2014) Semin Oncol, 41, pp. S1-S14; Stupp, R., Taillibert, S., Kanner, A., Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial (2017) JAMA, 318, pp. 2306-2316; Taphoorn, M.J.B., Dirven, L., Kanner, A.A., Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial (2018) JAMA Oncol, 4, pp. 495-504; Ceresoli, G.L., Vergote, I., Rivera, F., Pless, M., Safety of Tumor Treating Fields delivery to the torso: pooled analysis from TTFields clinical trials. Proceedings of the 110th Annual Meeting of the American Association for Cancer Research; Atlanta, GA; March 29–April 3, 2019 (abstr CT202); Giladi, M., Munster, M., Blat, R., In vitro results and electric fields simulations suggest Tumor Treating Fields (TTFields) to be an effective treatment against mesothelioma. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; Philadelphia, PA; April 18–22, 2015 (abstr 5361); Byrne, M.J., Nowak, A.K., Modified RECIST criteria for assessment of response in malignant pleural mesothelioma (2004) Ann Oncol, 15, pp. 257-260; Scherpereel, A., Wallyn, F., Albelda, S.M., Munck, C., Novel therapies for malignant pleural mesothelioma (2018) Lancet Oncol, 19, pp. e161-e172; Stupp, R., Taillibert, S., Kanner, A., Maintenance therapy with Tumor-Treating Fields plus temozolomide vs temozolomide alone for glioblastoma (2015) JAMA, 314, pp. 2535-2543; Pless, M., Droege, C., von Moos, R., A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer (2013) Lung Cancer, 81, pp. 445-450; Ceresoli, G.L., Castagneto, B., Zucali, P.A., Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials (2008) Br J Cancer, 99, pp. 51-56; Grosso, F., Steele, N., Novello, S., Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial (2017) J Clin Oncol, 35, pp. 3591-3600; Scagliotti, G.V., Gaafar, R., Nowak, A.K., Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial (2019) Lancet Res Med, 7, pp. 569-580; Curran, D., Sahmoud, T., Therasse, P., Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment Cancer experience (1998) J Clin Oncol, 16, pp. 145-152; Rusch, V.W., Giroux, D., Kennedy, C., Initial analysis of the international association for the study of lung cancer mesothelioma database (2012) J Thorac Oncol, 7, pp. 1631-1639; Levin, P.A., Dowell, J.E., Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date (2017) Onco Targets Ther, 10, pp. 2057-2066",
year = "2019",
doi = "10.1016/S1470-2045(19)30532-7",
language = "English",
volume = "20",
pages = "1702--1709",
journal = "Lancet Oncol.",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "12",
}